Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.74
TSRO's Cash-to-Debt is ranked lower than
82% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. TSRO: 0.74 )
Ranked among companies with meaningful Cash-to-Debt only.
TSRO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.74  Med: 4.36 Max: No Debt
Current: 0.74
0.74
No Debt
Equity-to-Asset -0.18
TSRO's Equity-to-Asset is ranked lower than
93% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. TSRO: -0.18 )
Ranked among companies with meaningful Equity-to-Asset only.
TSRO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18  Med: 0.48 Max: 0.73
Current: -0.18
-0.18
0.73
Debt-to-Equity -4.92
TSRO's Debt-to-Equity is ranked lower than
99.99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. TSRO: -4.92 )
Ranked among companies with meaningful Debt-to-Equity only.
TSRO' s Debt-to-Equity Range Over the Past 10 Years
Min: -29.7  Med: 0.58 Max: 3.74
Current: -4.92
-29.7
3.74
Debt-to-EBITDA -1.11
TSRO's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. TSRO: -1.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TSRO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.11  Med: -0.59 Max: -0.35
Current: -1.11
-1.11
-0.35
Piotroski F-Score: 2
Altman Z-Score: -2.52
Beneish M-Score: -3.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -283.27
TSRO's Operating Margin % is ranked lower than
54% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. TSRO: -283.27 )
Ranked among companies with meaningful Operating Margin % only.
TSRO' s Operating Margin % Range Over the Past 10 Years
Min: -74461.2  Med: -827.59 Max: -214.72
Current: -283.27
-74461.2
-214.72
Net Margin % -295.67
TSRO's Net Margin % is ranked lower than
55% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. TSRO: -295.67 )
Ranked among companies with meaningful Net Margin % only.
TSRO' s Net Margin % Range Over the Past 10 Years
Min: -79308.52  Med: -864.45 Max: -222.15
Current: -295.67
-79308.52
-222.15
ROE % -521.54
TSRO's ROE % is ranked lower than
91% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. TSRO: -521.54 )
Ranked among companies with meaningful ROE % only.
TSRO' s ROE % Range Over the Past 10 Years
Min: -521.54  Med: -125.85 Max: -77.35
Current: -521.54
-521.54
-77.35
ROA % -85.37
TSRO's ROA % is ranked lower than
76% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. TSRO: -85.37 )
Ranked among companies with meaningful ROA % only.
TSRO' s ROA % Range Over the Past 10 Years
Min: -96.85  Med: -70.76 Max: -38.24
Current: -85.37
-96.85
-38.24
ROC (Joel Greenblatt) % -5840.55
TSRO's ROC (Joel Greenblatt) % is ranked lower than
78% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. TSRO: -5840.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TSRO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -36654.6  Med: -13072.88 Max: -5831.62
Current: -5840.55
-36654.6
-5831.62
3-Year EBITDA Growth Rate -22.10
TSRO's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. TSRO: -22.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TSRO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.8  Med: -30.7 Max: -11.3
Current: -22.1
-59.8
-11.3
3-Year EPS without NRI Growth Rate -24.20
TSRO's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. TSRO: -24.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TSRO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40.7  Med: -31.55 Max: -11.7
Current: -24.2
-40.7
-11.7
GuruFocus has detected 3 Warning Signs with Tesaro Inc TSRO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TSRO's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

TSRO Guru Trades in Q1 2018

Pioneer Investments 7,790 sh (+1.47%)
Vanguard Health Care Fund 2,996,631 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 186,500 sh (-47.82%)
» More
Q2 2018

TSRO Guru Trades in Q2 2018

Steven Cohen 358,900 sh (New)
Vanguard Health Care Fund 3,099,228 sh (+3.42%)
Jim Simons 292,600 sh (+56.89%)
Pioneer Investments Sold Out
» More
Q3 2018

TSRO Guru Trades in Q3 2018

Vanguard Health Care Fund 4,099,228 sh (+32.27%)
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q4 2018

TSRO Guru Trades in Q4 2018

Mario Gabelli 97,450 sh (New)
Pioneer Investments 5,500 sh (New)
Vanguard Health Care Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TSRO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:LOXO, SHSE:603233, NAS:LGND, NAS:ARRY, XKRX:086900, LSE:ABC, LSE:BTG, XKRX:084990, NAS:AAAP, XTER:MOR, HKSE:00570, SZSE:000990, NAS:CLVS, SZSE:002603, SZSE:300347, XSWX:IDIA, NAS:ACAD, SHSE:600161, NAS:FGEN, SZSE:300009 » details
Traded in other countries:T8S.Germany,
Headquarter Location:USA
Tesaro Inc is an oncology-focused biopharmaceutical company. It focuses on developing treatments for cancer.

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Top Ranked Articles about Tesaro Inc

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TSRO and MGI
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro, Inc. of Class Action Lawsuit and Upcoming Deadline – TSRO
DEADLINE NEXT WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
CLASS ACTION UPDATE for TSRO, PPDF and MAR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro, Inc. of Class Action Lawsuit and Upcoming Deadline – TSRO
TSRO LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tesaro, Inc.; Important Case Deadline – TSRO
EARLY JANUARY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tesaro, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro, Inc. of Class Action Lawsuit and Upcoming Deadline - TSRO
CLASS ACTION UPDATE for TSRO, EIX and MDR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Ratios

vs
industry
vs
history
PS Ratio 18.70
TSRO's PS Ratio is ranked higher than
70% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TSRO: 18.70 )
Ranked among companies with meaningful PS Ratio only.
TSRO' s PS Ratio Range Over the Past 10 Years
Min: 4.88  Med: 115.87 Max: 29065
Current: 18.7
4.88
29065
EV-to-EBIT -7.30
TSRO's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. TSRO: -7.30 )
Ranked among companies with meaningful EV-to-EBIT only.
TSRO' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.7  Med: -7.9 Max: -2.6
Current: -7.3
-24.7
-2.6
EV-to-EBITDA -7.42
TSRO's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. TSRO: -7.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
TSRO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.9  Med: -7.9 Max: -2.7
Current: -7.42
-24.9
-2.7
EV-to-Revenue 19.58
TSRO's EV-to-Revenue is ranked higher than
72% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. TSRO: 19.58 )
Ranked among companies with meaningful EV-to-Revenue only.
TSRO' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.1  Med: 112.4 Max: 24675.3
Current: 19.58
5.1
24675.3
Current Ratio 3.40
TSRO's Current Ratio is ranked lower than
53% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. TSRO: 3.40 )
Ranked among companies with meaningful Current Ratio only.
TSRO' s Current Ratio Range Over the Past 10 Years
Min: 3.4  Med: 10.4 Max: 31.29
Current: 3.4
3.4
31.29
Quick Ratio 2.83
TSRO's Quick Ratio is ranked lower than
54% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. TSRO: 2.83 )
Ranked among companies with meaningful Quick Ratio only.
TSRO' s Quick Ratio Range Over the Past 10 Years
Min: 2.83  Med: 10.3 Max: 31.29
Current: 2.83
2.83
31.29
Days Inventory 375.59
TSRO's Days Inventory is ranked lower than
86% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. TSRO: 375.59 )
Ranked among companies with meaningful Days Inventory only.
TSRO' s Days Inventory Range Over the Past 10 Years
Min: 280.3  Med: 753.15 Max: 927.22
Current: 375.59
280.3
927.22
Days Sales Outstanding 52.18
TSRO's Days Sales Outstanding is ranked higher than
69% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. TSRO: 52.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
TSRO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.51  Med: 87.3 Max: 781.81
Current: 52.18
43.51
781.81
Days Payable 139.48
TSRO's Days Payable is ranked higher than
52% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. TSRO: 139.48 )
Ranked among companies with meaningful Days Payable only.
TSRO' s Days Payable Range Over the Past 10 Years
Min: 32.2  Med: 614.32 Max: 10921.4
Current: 139.48
32.2
10921.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.70
TSRO's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. TSRO: -14.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TSRO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.9  Med: -14.4 Max: -10.6
Current: -14.7
-17.9
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.16
TSRO's Price-to-Median-PS-Value is ranked higher than
98% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. TSRO: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TSRO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.98 Max: 174.35
Current: 0.16
0.07
174.35
Earnings Yield (Greenblatt) % -13.70
TSRO's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. TSRO: -13.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TSRO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -38.1  Med: -12.65 Max: -4.1
Current: -13.7
-38.1
-4.1

More Statistics

Revenue (TTM) (Mil) $219.37
EPS (TTM) $ -11.86
Volatility103.01%
52-Week Range $23.41 - 75.16
Shares Outstanding (Mil)55.07

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 263 396 607 756
EBIT (Mil $)
EBITDA (Mil $) -555 -514 -448 -362
EPS ($) -11.02 -8.03 -3.82 -1.68
EPS without NRI ($) -11.02 -8.03 -3.82 -1.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}